卵巢癌早期检测方案的设计。
Designing early detection programs for ovarian cancer.
机构信息
Molecular Diagnostics Program, Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N., Seattle, WA 98109, USA.
出版信息
Ann Oncol. 2011 Dec;22 Suppl 8(Suppl 8):viii6-viii18. doi: 10.1093/annonc/mdr472.
Abstract
Human epididymis protein 4 (HE4) shows promise as a serum marker that complements CA125 in the early detection of epithelial ovarian cancer, either as a first-line screen or as a second-line screen in a multimodal strategy. Incorporation of symptoms in a screening strategy that includes CA125 and HE4 may warrant further research.
摘要
人附睾蛋白 4（HE4）作为一种血清标志物，在早期检测上皮性卵巢癌方面具有与 CA125 互补的潜力，可以作为一线筛查，也可以作为多模式策略中的二线筛查。将症状纳入包括 CA125 和 HE4 的筛查策略中可能需要进一步研究。
相似文献
1
Designing early detection programs for ovarian cancer.卵巢癌早期检测方案的设计。
Ann Oncol. 2011 Dec;22 Suppl 8(Suppl 8):viii6-viii18. doi: 10.1093/annonc/mdr472.
2
Use of CA125 and HE4 serum markers to predict ovarian cancer in elevated-risk women.使用CA125和HE4血清标志物预测高危女性的卵巢癌。
Cancer Epidemiol Biomarkers Prev. 2014 Jul;23(7):1383-93. doi: 10.1158/1055-9965.EPI-13-1361. Epub 2014 May 1.
3
Human epididymis protein 4 antigen-autoantibody complexes complement cancer antigen 125 for detecting early-stage ovarian cancer.人附睾蛋白 4 抗原-自身抗体复合物补充肿瘤标志物 CA125 用于检测早期卵巢癌。
Cancer. 2020 Feb 15;126(4):725-736. doi: 10.1002/cncr.32582. Epub 2019 Nov 12.
4
Validation of a Novel Biomarker Panel for the Detection of Ovarian Cancer.用于检测卵巢癌的新型生物标志物组合的验证
Cancer Epidemiol Biomarkers Prev. 2016 Sep;25(9):1333-40. doi: 10.1158/1055-9965.EPI-15-1299. Epub 2016 Jul 22.
5
HE4--a novel promising serum marker in the diagnosis of ovarian carcinoma.人附睾蛋白4——一种在卵巢癌诊断中颇具前景的新型血清标志物。
Eur J Gynaecol Oncol. 2011;32(6):605-10.
6
A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.一种多重生物标志物检测方法提高了 HE4 和 CA125 在卵巢肿瘤患者中的诊断性能。
PLoS One. 2020 Oct 19;15(10):e0240418. doi: 10.1371/journal.pone.0240418. eCollection 2020.
7
Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response.HE4 评估与 CA125 比较在卵巢癌诊断和治疗反应评估中的意义。
Diagn Pathol. 2013 Jan 23;8:11. doi: 10.1186/1746-1596-8-11.
8
The value of 18F-FDG PET/CT imaging combined with detection of CA125 and HE4 in the diagnosis of recurrence and metastasis of ovarian cancer.18F-FDG PET/CT 显像联合 CA125 和 HE4 检测在卵巢癌复发转移诊断中的价值。
Eur Rev Med Pharmacol Sci. 2020 Jul;24(13):7276-7283. doi: 10.26355/eurrev_202007_21882.
9
Diagnostic accuracy of CA125 and HE4 in ovarian carcinoma patients and the effect of confounders on their serum levels.CA125 和 HE4 对卵巢癌患者的诊断准确性及混杂因素对其血清水平的影响。
Curr Probl Cancer. 2019 Oct;43(5):450-460. doi: 10.1016/j.currproblcancer.2018.12.004. Epub 2019 Jan 16.
10
The differential diagnostic value and clinical significance of serum HE4 in ovarian disease with elevated CA125.血清 HE4 在 CA125 升高的卵巢疾病中的鉴别诊断价值及临床意义。
Arch Gynecol Obstet. 2020 May;301(5):1219-1225. doi: 10.1007/s00404-020-05527-0. Epub 2020 Apr 7.
引用本文的文献
1
Diagnostic value of serum human epididymis protein 4 in esophageal squamous cell carcinoma.血清人附睾蛋白4在食管鳞状细胞癌中的诊断价值
World J Gastrointest Oncol. 2020 Oct 15;12(10):1167-1176. doi: 10.4251/wjgo.v12.i10.1167.
2
Retrospective Study of the Epidemiology, Pathology, and Therapeutic Management in Patients With Mucinous Ovarian Tumors.黏液性卵巢肿瘤患者的流行病学、病理学和治疗管理的回顾性研究。
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820946423. doi: 10.1177/1533033820946423.
3
Expression and diagnostic value of HE4 in pancreatic adenocarcinoma.人附睾蛋白4在胰腺腺癌中的表达及诊断价值
Int J Mol Sci. 2015 Jan 29;16(2):2956-70. doi: 10.3390/ijms16022956.
4
The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomas.HE4 在评估上皮性卵巢癌和子宫内膜癌中的新兴作用。
Oncology (Williston Park). 2013 Jun;27(6):548-56.
5
Usefulness of the HE4 biomarker as a second-line test in the assessment of suspicious ovarian tumors.HE4 标志物作为二线检测在可疑卵巢肿瘤评估中的作用。
Arch Gynecol Obstet. 2013 Dec;288(6):1377-83. doi: 10.1007/s00404-013-2901-1. Epub 2013 May 31.
6
Interpretation of single and serial measures of HE4 and CA125 in asymptomatic women at high risk for ovarian cancer.无症状高危卵巢癌女性的 HE4 和 CA125 单次和连续测量的解读。
Cancer Epidemiol Biomarkers Prev. 2012 Nov;21(11):2087-94. doi: 10.1158/1055-9965.EPI-12-0616. Epub 2012 Sep 7.
本文引用的文献
1
A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer.用于早期检测的生物标志物评估框架：卵巢癌生物标志物组合的验证。
Cancer Prev Res (Phila). 2011 Mar;4(3):375-83. doi: 10.1158/1940-6207.CAPR-10-0193.
2
Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens.在前列腺癌、肺癌、结直肠癌和卵巢癌筛查试验标本中卵巢癌生物标志物的性能。
Cancer Prev Res (Phila). 2011 Mar;4(3):365-74. doi: 10.1158/1940-6207.CAPR-10-0195.
3
HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses.人附睾蛋白4和间皮素：盆腔肿块患者卵巢癌的新型生物标志物。
Asian Pac J Cancer Prev. 2010;11(1):111-6.
4
Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass.新型多指标联合检测与风险恶性指数在盆腔包块患者上皮性卵巢癌预测中的比较。
Am J Obstet Gynecol. 2010 Sep;203(3):228.e1-6. doi: 10.1016/j.ajog.2010.03.043. Epub 2010 May 14.
5
Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study.评估选定卵巢癌生物标志物的领先时间：一项巢式病例对照研究。
J Natl Cancer Inst. 2010 Jan 6;102(1):26-38. doi: 10.1093/jnci/djp438. Epub 2009 Dec 30.
6
Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer.使用症状指数、CA125和HE4预测卵巢癌。
Gynecol Oncol. 2010 Mar;116(3):378-83. doi: 10.1016/j.ygyno.2009.10.087. Epub 2009 Nov 28.
7
The utility of serum human epididymis protein 4 (HE4) in patients with a pelvic mass.血清人附睾蛋白 4（HE4）在盆腔肿块患者中的应用。
J Clin Lab Anal. 2009;23(5):331-5. doi: 10.1002/jcla.20340.
8
Results from four rounds of ovarian cancer screening in a randomized trial.一项随机试验中四轮卵巢癌筛查的结果。
Obstet Gynecol. 2009 Apr;113(4):775-782. doi: 10.1097/AOG.0b013e31819cda77.
9
Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).多模式及超声筛查卵巢癌的敏感性和特异性，以及所检测癌症的分期分布：英国卵巢癌筛查协作试验（UKCTOCS）患病率筛查结果
Lancet Oncol. 2009 Apr;10(4):327-40. doi: 10.1016/S1470-2045(09)70026-9. Epub 2009 Mar 11.
10
A parametric empirical Bayes method for cancer screening using longitudinal observations of a biomarker.一种使用生物标志物纵向观测数据进行癌症筛查的参数经验贝叶斯方法。
Biostatistics. 2003 Jan;4(1):27-40. doi: 10.1093/biostatistics/4.1.27.
Zotero 插件